0000950170-24-138629.txt : 20241219 0000950170-24-138629.hdr.sgml : 20241219 20241219185742 ACCESSION NUMBER: 0000950170-24-138629 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20241218 FILED AS OF DATE: 20241219 DATE AS OF CHANGE: 20241219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: AULIN SHERRY CENTRAL INDEX KEY: 0001862144 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36687 FILM NUMBER: 241564680 MAIL ADDRESS: STREET 1: 200 - 3650 GILMORE WAY CITY: BURNABY STATE: A0 ZIP: V5G 48W ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Xenon Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001582313 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980661854 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 - 3650 GILMORE WAY CITY: BURNABY STATE: A1 ZIP: V5G 48W BUSINESS PHONE: (604) 484-3300 MAIL ADDRESS: STREET 1: 200 - 3650 GILMORE WAY CITY: BURNABY STATE: A1 ZIP: V5G 48W 4 1 ownership.xml 4 X0508 4 2024-12-18 false 0001582313 Xenon Pharmaceuticals Inc. XENE 0001862144 AULIN SHERRY 200 - 3650 GILMORE WAY BURNABY A1 V5G 4W8 BRITISH COLUMBIA, CANADA false true false false Chief Financial Officer false Common Shares 2024-12-18 4 M false 9334 9.44 A 9334 D Common Shares 2024-12-18 4 F false 2135 41.28 D 7199 D Common Shares 2024-12-18 4 S false 7199 41.23 D 0 D Common Shares 2024-12-18 4 M false 16000 11.58 A 16000 D Common Shares 2024-12-18 4 F false 4490 41.28 D 11510 D Common Shares 2024-12-18 4 S false 11510 41.19 D 0 D Stock Option (Right to Buy) 9.44 2024-12-18 4 M false 9334 0 D 2029-09-15 Common Shares 9334 0 D Stock Option (Right to Buy) 11.58 2024-12-18 4 M false 16000 0 D 2030-03-11 Common Shares 16000 6000 D Represents the closing price of the Company's common shares on December 17, 2024 for purposes of net settlement calculations. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.19 to $41.20, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. The shares subject to the option are fully vested and exercisable. /s/ Nathaniel Adams, Attorney-in-fact 2024-12-18